Life-changing mobility drug for spinal muscular atrophy patients to be available on NHS

Around 1,500 SMA patients will have access to ‘important’ oral medication in England . Rory Sulivan writes

Friday 19 November 2021 09:11
Comments
<p>Melvil Vedrenne-Cloquet, 9, who has spinal muscular atrophy, is pictured in hospital. </p>

Melvil Vedrenne-Cloquet, 9, who has spinal muscular atrophy, is pictured in hospital.

A medicine which aims to boost the mobility of people with spinal muscular atrophy (SMA) will soon be provided on the NHS, it has been announced.

The rare genetic condition, which gets worse over time, inhibits movement by causing muscle weakness.

Risdiplam, whose cost price is almost £8,000 per 80ml bottle, will become available to roughly 1,500 SMA sufferers across the country, after NHS England struck an agreement with its manufacturer, the pharmaceutical giant Roche.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in